THE US Food and Drug Administration (FDA) has expanded the approval of Imbruvica (ibrutinib) to include the treatment of adult patients with chronic graft versus host disease (cGVHD) under specific conditions, the first FDA-approved therapy for cGVHD.
Visit fda.gov for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 17
